Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Boston Scientific (BSX) Gets a Buy from Canaccord Genuity

Tipranks - Tipranks - Tue Mar 31, 8:49AM CDT

Canaccord Genuity analyst William Plovanic maintained a Buy rating on Boston Scientific today and set a price target of $109.00.

End of Quarter Sale - 50% Off TipRanks

Plovanic covers the Healthcare sector, focusing on stocks such as HeartFlow, Inc., TransMedics Group, and Boston Scientific. According to TipRanks, Plovanic has an average return of 1.2% and a 39.88% success rate on recommended stocks.

In addition to Canaccord Genuity, Boston Scientific also received a Buy from Evercore ISI’s Vijay Kumar in a report issued today. However, on March 17, TipRanks – xAI reiterated a Hold rating on Boston Scientific (NYSE: BSX).

See Insiders’ Hot Stocks on TipRanks >>

Based on Boston Scientific’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.29 billion and a net profit of $668 million. In comparison, last year the company earned a revenue of $4.56 billion and had a net profit of $566 million

Read More on BSX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).